Literature DB >> 18336256

Advances in the structural understanding of Vif proteins.

Pierre Barraud1, Jean-Christophe Paillart, Roland Marquet, Carine Tisné.   

Abstract

The multidomain HIV-1 Vif protein recruits several cellular partners to achieve neutralization of the antiviral activity of APOBEC3 proteins. Vif neutralizes APOBEC3G and APOBEC3F predominantly by forming an E3 ubiquitin ligase with Cullin5, ElonginB and ElonginC that targets these proteins for degradation by the ubiquitin-proteasome pathway. Vif associates with the Cullin5-ElonginB-ElonginC complex by binding directly to ElonginC via its SOCS-box motif and to Cullin5 via hydrophobic residues within a zinc-binding region formed by a conserved HCCH motif. The HIV-1 Vif-Cullin5-ElonginBC complex is then able to ubiquitinate the APOBEC3G factor bound to Vif by its N-terminal domain. In this review, we summarize the current knowledge about the structural determinants of Vif that allow it to interact with cellular and viral partners.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18336256      PMCID: PMC2704546          DOI: 10.2174/157016208783885056

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  88 in total

Review 1.  SCF and Cullin/Ring H2-based ubiquitin ligases.

Authors:  R J Deshaies
Journal:  Annu Rev Cell Dev Biol       Date:  1999       Impact factor: 13.827

2.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

3.  Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.

Authors:  Andrew Mehle; Joao Goncalves; Mariana Santa-Marta; Mark McPike; Dana Gabuzda
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

4.  Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.

Authors:  Bin Yang; Ling Gao; Lin Li; Zhixian Lu; Xuejun Fan; Charvi A Patel; Roger J Pomerantz; Garrett C DuBois; Hui Zhang
Journal:  J Biol Chem       Date:  2002-12-11       Impact factor: 5.157

5.  Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.

Authors:  Bärbel Schröfelbauer; Tilo Senger; Gerard Manning; Nathaniel R Landau
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity.

Authors:  A M Borman; C Quillent; P Charneau; C Dauguet; F Clavel
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

8.  Nucleotide sequence analysis of equine infectious anemia virus proviral DNA.

Authors:  T Kawakami; L Sherman; J Dahlberg; A Gazit; A Yaniv; S R Tronick; S A Aaronson
Journal:  Virology       Date:  1987-06       Impact factor: 3.616

9.  Cooperative and specific binding of Vif to the 5' region of HIV-1 genomic RNA.

Authors:  Simon Henriet; Delphine Richer; Serena Bernacchi; Etienne Decroly; Robert Vigne; Bernard Ehresmann; Chantal Ehresmann; Jean-Christophe Paillart; Roland Marquet
Journal:  J Mol Biol       Date:  2005-10-03       Impact factor: 5.469

10.  A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.

Authors:  Hongzhan Xu; Evguenia S Svarovskaia; Rebekah Barr; Yijun Zhang; Mohammad A Khan; Klaus Strebel; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

View more
  29 in total

1.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

2.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

3.  Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Authors:  Tao Zuo; Donglai Liu; Wei Lv; Xiaodan Wang; Jiawen Wang; Mingyu Lv; Wenlin Huang; Jiaxin Wu; Haihong Zhang; Hongwei Jin; Liangren Zhang; Wei Kong; Xianghui Yu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 4.  Structural insights for HIV-1 therapeutic strategies targeting Vif.

Authors:  Jason D Salter; Guillermo A Morales; Harold C Smith
Journal:  Trends Biochem Sci       Date:  2014-08-12       Impact factor: 13.807

5.  Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.

Authors:  Dona Sleiman; Serena Bernacchi; Santiago Xavier Guerrero; Franck Brachet; Valéry Larue; Jean-Christophe Paillart; Carine Tisne
Journal:  RNA Biol       Date:  2014-07-22       Impact factor: 4.652

6.  Core-binding factor β increases the affinity between human Cullin 5 and HIV-1 Vif within an E3 ligase complex.

Authors:  Jason D Salter; Geoffrey M Lippa; Ivan A Belashov; Joseph E Wedekind
Journal:  Biochemistry       Date:  2012-10-25       Impact factor: 3.162

7.  The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex.

Authors:  Julien R C Bergeron; Hendrik Huthoff; Dennis A Veselkov; Rebecca L Beavil; Peter J Simpson; Stephen J Matthews; Michael H Malim; Mark R Sanderson
Journal:  PLoS Pathog       Date:  2010-06-03       Impact factor: 6.823

8.  Sequence alignment reveals possible MAPK docking motifs on HIV proteins.

Authors:  Perry Evans; Ahmet Sacan; Lyle Ungar; Aydin Tozeren
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

9.  HIV-1 Vpr oligomerization but not that of Gag directs the interaction between Vpr and Gag.

Authors:  Joëlle V Fritz; Denis Dujardin; Julien Godet; Pascal Didier; Jan De Mey; Jean-Luc Darlix; Yves Mély; Hugues de Rocquigny
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

10.  HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation.

Authors:  Gaëlle Mercenne; Serena Bernacchi; Delphine Richer; Guillaume Bec; Simon Henriet; Jean-Christophe Paillart; Roland Marquet
Journal:  Nucleic Acids Res       Date:  2009-11-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.